• EBITDA guidance reaffirmed for FY2026 at A$1.87 - 1.95 billion
• Depreciation and interest expense guidance updated
• FY2025 performance highlights including 5% organic revenue growth and 40bps EBITDA margin expansion
• Acquisition of LADR laboratory group in Germany

Sonic Healthcare has provided an update on its FY2026 guidance and FY2025 performance at its 2025 Annual General Meeting. The company has reaffirmed its EBITDA guidance for FY2026 at A$1.87 - 1.95 billion, reflecting up to 13% growth on FY2025 on a constant currency basis. This guidance includes an expected H1 weighting of approximately 45-46% of the full year, consistent with historical seasonality. Sonic has also updated its depreciation and interest expense guidance, with depreciation forecast at A$780 - 790 million and interest expense increase expected to be at the lower end of the 15 - 20% range. Other guidance considerations include an effective tax rate of ~27% and the exclusion of potential PAMA fee reductions in the USA. In FY2025, Sonic achieved its EBITDA earnings guidance, with 5% organic revenue growth and a 40bps expansion in normalised EBITDA margin. The company has also announced the acquisition of the LADR laboratory group in Germany, a major growth milestone for Sonic's 20-year presence in the country. LADR is a highly reputable, third-generation family-owned group with annual revenue of ~€370 million and EBITDA of ~€50 million, and the acquisition is expected to be immediately EPS accretive with a strong post-synergy return on investment.

EBITDA guidance for FY2026 of A$1.87 - 1.95 billion (constant currency), reflecting up to 13% growth on FY2025. Depreciation expense forecast at A$780 - 790 million (constant currency) and interest expense increase expected to be at the lower end of 15 - 20% (constant currency).

Sonic Healthcare is well-positioned for continued growth, driven by organic growth opportunities in personalised and precision medicine, new and expanding markets, and targeted acquisitions of high-quality medical practices. The company's focus on medical excellence and scale is also driving efficiencies and earnings growth.